☆ 4.7 Article

Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines tor diagnosis, treatment and follow-up

ANNALS OF ONCOLOGY (2020)

Journal

ANNALS OF ONCOLOGY

Volume 31, Issue 6, Pages 697-712

Publisher

ELSEVIER

DOI: 10.1016/j.annonc.2020.02.018

Keywords

guideline; treatment recommendation; dosing information; acute myeloid leukaemia; European LeukaemiaNet; World Health Organization

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Medicine, General & Internal

Acute myeloid leukaemia

Courtney D. Dinardo, Harry P. Erba, Sylvie D. Freeman, Andrew H. Wei

Summary: Progress in acute myeloid leukaemia treatment has seen significant improvements in scientific understanding, prognostication tools, risk assessments, and incorporation of measurable residual disease into risk assessments. Recent updates in classification and recommendations by organizations such as WHO, ICC, and European LeukemiaNet have provided enhanced guidance for prognostic stratification and treatment response assessment. There have also been advancements in treatment options, leading to improved outcomes for both newly diagnosed and relapsed patients.

LANCET (2023)

Add to Collection

Article Multidisciplinary Sciences

Subtype-specific 3D genome alteration in acute myeloid leukaemia

Jie Xu, Fan Song, Huijue Lyu, Mikoto Kobayashi, Baozhen Zhang, Ziyu Zhao, Ye Hou, Xiaotao Wang, Yu Luan, Bei Jia, Lena Stasiak, Josiah Hiu-yuen Wong, Qixuan Wang, Qi Jin, Qiushi Jin, Yihao Fu, Hongbo Yang, Ross C. Hardison, Sinisa Dovat, Leonidas C. Platanias, Yarui Diao, Yue Yang, Tomoko Yamada, Aaron D. Viny, Ross L. Levine, David Claxton, James R. Broach, Hong Zheng, Feng Yue

Summary: This study uses Hi-C and whole-genome sequencing to analyze samples from AML patients and healthy donors, revealing recurrent and subtype-specific alterations in chromatin structure and loops. Functional validation and manipulation of DNA methylation further highlight the role of repressive loops and hijacked cis elements in AML.

NATURE (2022)

Add to Collection

Article Multidisciplinary Sciences

Epitope editing enables targeted immunotherapy of acute myeloid leukaemia

Gabriele Casirati, Andrea Cosentino, Adele Mucci, Mohammed Salah Mahmoud, Iratxe Ugarte Zabala, Jing Zeng, Scott B. Ficarro, Denise Klatt, Christian Brendel, Alessandro Rambaldi, Jerome Ritz, Jarrod A. Marto, Danilo Pellin, Daniel E. Bauer, Scott A. Armstrong, Pietro Genovese

Summary: Epitope engineering of donor haematopoietic stem/progenitor cells endows haematopoietic lineages with selective resistance to CAR T cells or monoclonal antibodies, without affecting protein function or regulation, enabling the targeting of genes that are essential for leukaemia survival and reducing the risk of tumour immune escape.

NATURE (2023)

Add to Collection

Review Pharmacology & Pharmacy

Targeting integrins in drug-resistant acute myeloid leukaemia

Heather A. Ogana, Samantha Hurwitz, Nathan Wei, Eliana Lee, Kayla Morris, Karina Parikh, Yong-Mi Kim

Summary: Acute myeloid leukaemia (AML) has a poor prognosis and new therapeutic strategies are needed. The bone marrow (BM) microenvironment contains niches that interact with both normal haematopoietic stem cells and AML cells. Integrins, which are adhesion molecules in the BM microenvironment, play a central role in AML. AML cells express integrins that bind to ligands in the microenvironment, leading to adhesion, intracellular signalling, and drug resistance. Targeting integrins in AML to disrupt interactions with the microenvironment is being explored as a strategy to overcome drug resistance.

BRITISH JOURNAL OF PHARMACOLOGY (2023)

Add to Collection

Review Pharmacology & Pharmacy

Targeting mitochondrial proteases for therapy of acute myeloid leukaemia

Xinrong Xiang, Rui Bao, Yu Wu, Youfu Luo

Summary: This article comprehensively reviews the role of mitochondrial proteases in acute myeloid leukemia (AML), highlighting their biological function, chemical modulators, and applicative prospects in AML.

BRITISH JOURNAL OF PHARMACOLOGY (2022)

Add to Collection

Review Hematology

Updates on targeted therapies for acute myeloid leukaemia

Sabine Kayser, Mark J. Levis

Summary: Research on the pathogenic mechanisms of AML has made remarkable advances in recent years, especially in the importance of cytogenetic and molecular aberrations. The development of new compounds targeting AML at a molecular level, based on increased understanding of AML pathogenesis facilitated by next-generation sequencing, has turned many hopeful predictions into therapeutic realities.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

Bipartite network models to design combination therapies in acute myeloid leukaemia

Mohieddin Jafari, Mehdi Mirzaie, Jie Bao, Farnaz Barneh, Shuyu Zheng, Johanna Eriksson, Caroline A. Heckman, Jing Tang

Summary: This study proposes a bipartite network modelling approach to identify effective drug combinations for the treatment of acute myeloid leukaemia. By analyzing patient and cell line drug screening data, the authors discover multi-targeted drug combinations and validate their potency and synergy through in vitro experiments.

NATURE COMMUNICATIONS (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Multiplex Screening for Interacting Compounds in Paediatric Acute Myeloid Leukaemia

Lauren Cairns, Katrina M. Lappin, Alexander Mutch, Ahlam Ali, Kyle B. Matchett, Ken Mills

Summary: Paediatric acute myeloid leukaemia (AML) is a complex disease with limited treatment options due to longstanding standard therapies and inadequate understanding of its biology. Recent advancements in genomic technologies have accelerated the search for new targets for paediatric AML treatment. Exploiting drug combinations through innovative screening strategies may offer new therapeutic options for paediatric AML.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Editorial Material Hematology

Acute myeloid leukaemia in Afghanistan: Understanding an unfamiliar landscape

Robert K. Hills

Summary: The paper by Noor et al. presents significant findings on the incidence and outcomes of patients with acute myeloid leukaemia in Afghanistan. It highlights the lower age of patients compared to the Western standard, reflecting the unique demographics of the country. These findings serve as an important initial step in identifying areas for improvement.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Mechanisms associated with t(7;12) acute myeloid leukaemia: from genetics to potential treatment targets

Denise Ragusa, Liza Dijkhuis, Cristina Pina, Sabrina Tosi

Summary: Acute myeloid leukaemia (AML) is a common disease in elderly adults, but it can also affect children, especially infants aged 0-2. Recurrent cytogenetic abnormalities play an important role in the development of leukaemia. The t(7;12)(q36;p13) translocation is a high-risk AML subtype associated exclusively with infants, but its underlying mechanisms are poorly understood. Abnormal expression of MNX1 in t(7;12) leukaemia has been studied, but its significance remains unclear.

BIOSCIENCE REPORTS (2023)

Add to Collection

Article Allergy

World Health Organization global air quality guideline recommendations: Executive summary

Anna Goshua, Cezmi Akdis, Kari C. Nadeau

Summary: Air pollution is a major cause of death globally, particularly affecting populations in low- and middle-income countries. The World Health Organization has published updated air quality guidelines to assist in improving air quality worldwide.

ALLERGY (2022)

Add to Collection

Article Pathology

Real world molecular characterisation and clonal evolution of acute myeloid leukaemia reveals therapeutic opportunities and challenges

Ricky Nelles, Louise Seymour, Joshua Richmond, Steven Lane

Summary: Acute myeloid leukaemia (AML) is an aggressive haematological malignancy with poor prognosis. This study aimed to review diagnostic testing of consecutive cases of AML in Queensland, Australia. The results showed a relatively high rate of missed FLT3 mutation testing at relapse, as well as FLT3 mutations being lost or gained, suggesting missed opportunities for salvage treatment strategies.

PATHOLOGY (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Survivin' Acute Myeloid Leukaemia-A Personalised Target for inv(16) Patients

Jochen Greiner, Elliott Brown, Lars Bullinger, Robert K. Hills, Vanessa Morris, Hartmut Doehner, Ken I. Mills, Barbara-ann Guinn

Summary: This study found that BIRC5 expression plays a role in the survival of AML patients, with above median levels associated with improved overall survival but not reaching statistical significance. Adjusted analyses showed a beneficial effect of high BIRC5 levels on overall survival. Additionally, decreased BIRC5 expression was associated with better clinical outcome.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Review Oncology

Crosstalk between DNA methylation and hypoxia in acute myeloid leukaemia

Sam Humphries, Danielle R. Bond, Zacary P. Germon, Simon Keely, Anoop K. Enjeti, Matthew D. Dun, Heather J. Lee

Summary: Hypoxia plays a role in influencing AML progression through interactions with DNA methylation, limiting the efficacy of hypomethylating agents within the hypoxic bone marrow. Co-treatments that promote cycling of AML cells within the bone marrow or encourage their dissociation from the bone marrow may be necessary for optimal outcomes in AML patients.

CLINICAL EPIGENETICS (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Targeting and Monitoring Acute Myeloid Leukaemia with Nucleophosmin-1 (NPM1) Mutation

Lynn Chin, Chantelle Ye Gwen Wong, Harinder Gill

Summary: Mutations in the NPM1 gene are commonly found in AML patients, and this review explores various molecular methods for monitoring minimal residual disease (MRD) in NPM1-mutated AML. It also discusses current and potential drug therapies, as well as targeted strategies for aberrant NPM1 pathways and epigenetic regulation. The effects of stress on AML presentation and the advancement of immunotherapy are also mentioned.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Letter Oncology

Clonal evolution in hereditary thrombocytosis with MPL T487A mutation

Loic Vasseur, Remi Favier, Rathana Kim, Florence Rabian, Aurelie Cabannes-Hamy, Bruno Cassinat, Nabih Maslah, Nadia Vasquez, Emmanuelle Clappier, Jean-Jacques Kiladjian, Nicolas Boissel

PEDIATRIC BLOOD & CANCER (2023)

Add to Collection

Article Biophysics

Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TC

Paul Chauvet, Annalisa Paviglianiti, Myriam Labopin, Helene Labussiere, Nicolas Boissel, Marie Robin, Natacha Maillard, Marie Ouachee-Chardin, Edouard Forcade, Xavier Poire, Sylvain Chantepie, Anne Huynh, Claude Eric Bulabois, Mathieu Leclerc, Sebastien Maury, Patrice Chevallier, Thomas Cluzeau, Jean-Baptiste Mear, Jerome Cornillon, Karin Bilger, Celestine Simand, Yves Beguin, Marie-Therese Rubio, Ibrahim Yakoub-Agha, Eolia Brissot

Summary: This study compared the efficacy and safety of blinatumomab with donor lymphocyte infusion (DLI) versus blinatumomab alone in relapsed B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic stem cell transplantation (allo-HCT). The results showed that adding DLI to blinatumomab treatment did not improve outcomes in B-ALL patients who relapsed after allo-HCT.

BONE MARROW TRANSPLANTATION (2023)

Add to Collection

Article Oncology

Compromised activity of natural killer cells in diffuse large b-cell lymphoma is related to lymphoma-induced modification of their surface receptor expression

Tehila Azoulay, Ilana Slouzky, Michal Karmona, Margarita Filatov, Michal Hayun, Yishai Ofran, Galit Sarig, Shimrit Ringelstein-Harlev

Summary: This study aimed to explore the functional properties of NK cells in DLBCL patients and found that the NK cells exhibited phenotypical skewing and restricted population. These functional abnormalities may support lymphoma immune evasion and disease propagation.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2023)

Add to Collection

Article Hematology

The increasingly blurred line between induction, consolidation and maintenance in acute myeloid leukaemia

Avi Frisch, Jacob M. Rowe, Yishai Ofran

Summary: Since the 1970s, the treatment of AML has evolved significantly, with progress in supportive care as well as the use of new drugs and allogeneic transplantation. The focus has shifted from maximal tolerated therapy to a more refined approach targeting patients who are more likely to respond. This has led to the development of new concepts and paradigms for AML treatment.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Article Oncology

Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study

Nicolas Boissel, Sabina Chiaretti, Cristina Papayannidis, Josep-Maria Ribera, Renato Bassan, Andrey N. Sokolov, Naufil Alam, Alessandra Brescianini, Isabella Pezzani, Georg Kreuzbauer, Gerhard Zugmaier, Robin Foa, Alessandro Rambaldi

Summary: This retrospective study included adult patients with B-cell ALL who were treated with blinatumomab for MRD+ or R/R B-cell ALL. The results showed significant treatment responses and survival benefits in both groups of patients.

BLOOD CANCER JOURNAL (2023)

Add to Collection

Article Hematology

Benefits of dexamethasone on early outcomes in patients with acute myeloid leukemia with hyperleukocytosis: a propensity score matched analysis

Marco Cerrano, Sylvie Chevret, Emmanuel Raffoux, Florence Rabian, Marie Sebert, Sandrine Valade, Raphael Itzykson, Virginie Lemiale, Lionel Ades, Nicolas Boissel, Herve Dombret, Elie Azoulay, Etienne Lengline

Summary: A study found that a short course of intravenous dexamethasone can reduce early mortality and improve overall survival in patients with hyperleukocytic acute myeloid leukemia (AML). The results of this study suggest that dexamethasone administration can be a promising strategy for treating high white blood cell AML.

ANNALS OF HEMATOLOGY (2023)

Add to Collection

Article Hematology

IL-7 receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK inhibition

Lucien Courtois, Aurelie Cabannes-Hamy, Rathana Kim, Marine Delecourt, Antoine Pinton, Guillaume Charbonnier, Melanie Feroul, Charlotte Smith, Giulia Tueur, Cecile Pivert, Estelle Balducci, Mathieu Simonin, Laure Helene Angel, Salvatore Spicuglia, Nicolas Boissel, Guillaume P. Andrieu, Vahid Asnafi, Philippe Rousselot, Ludovic Lhermitte

Summary: T-cell acute lymphoblastic leukemia (T-ALL) is a hematological malignancy with a poor prognosis, and IL-7R expression can be used as a biomarker for predicting sensitivity to JAK inhibitors.

BLOOD (2023)

Add to Collection

Article Hematology

Venetoclax-based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia

Jonathan Canaani, Avraham Frisch, Daniel A. Pollyea, Marc Schwartz, Shlomzion Aumann, Chezi Ganzel, Arnon Haran, Noa Gross Even-Zohar, Adir Shaulov, Vladimir Vainstein, Yakir Moshe, Yishai Ofran, Ofir Wolach, Boaz Nachmias

Summary: This study retrospectively analyzed the efficacy and safety of venetoclax-based chemotherapy or venetoclax-based navitoclax combination therapy in relapsed/refractory B or T ALL patients. The overall response rates were 55% and 46% for ven-chemotherapy and ven-navitoclax-chemotherapy, respectively. Most responders proceeded to bone marrow transplant. Adverse effects of the ven-navitoclax combination included infectious complications and hepatotoxicity.

EUROPEAN JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Article Oncology

Decreased melanoma CSF-1 secretion by Cannabigerol treatment reprograms regulatory myeloid cells and reduces tumor progression

Iris Wyrobnik, Miryam Steinberg, Anat Gelfand, Ronen Rosenblum, Yara Eid Mutlak, Liron Sulimani, Shiri Procaccia, Yishai Ofran, Hila Novak-Kotzer, David Meiri

Summary: During solid tumor progression, the tumor microenvironment (TME) becomes highly immunosuppressive, with regulatory myeloid cells, such as myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs), playing a key role. This study found that Cannabis extracts can decrease the secretion of colony-stimulating factor 1 (CSF-1) by melanoma cells, which is crucial for the recruitment and activation of MDSCs and TAMs. Specific cannabinoids, such as cannabigerol (CBG), were identified as responsible for this effect. Treatment with CBG reduced the expansion of MDSCs and restored CD8+ T-cell activation, leading to reduced tumor progression and enhanced immune response in tumor-bearing mice. Combination therapy with CBG and aPD-L1 showed even better results in reducing tumor progression and increasing the infiltration of activated cytotoxic T-cells. This study highlights the potential therapeutic value of CBG in modulating the tumor microenvironment and enhancing immune checkpoint blockade therapy.

ONCOIMMUNOLOGY (2023)

Add to Collection

Letter Oncology

Antitumoral effects of cannabis in Notch1-mutated T-cell acute lymphoblastic leukemia

Elazar Besser, Anat Gelfand, Gil Moshe Lewitus, Hila Novak-Kotzer, Shiri Procaccia, Paula Berman, Igal Louria-Hayon, Inbar Shreiber-Livne, Yishai Ofran, David Meiri

CANCER COMMUNICATIONS (2023)

Add to Collection

Letter Hematology

Real-world Experience of Approved Chimeric Antigen Receptor T-cell Therapies Compared to Clinical Trials Data

Jerome Lambert, Roberta Di Blasi, Florence Rabian, Marie-Emilie Dourthe, Andre Baruchel, Catherine Thieblemont, Nicolas Boissel, Vincent Levy, Marie-Quitterie Picat, Sylvie Chevret

HEMASPHERE (2023)

Add to Collection

Letter Hematology

Impact of T-cell Receptor Status on Mutational Landscape and Outcome in T-ALL

Marie Emilie Dourthe, Lucien Courtois, Guillaume P. Andrieu, Mathieu Simonin, Aurore Touzart, Ludovic Lhermitte, Arnaud Petit, Nicolas Boissel, Andre Baruchel, Vahid Asnafi, Elizabeth Macintyre

HEMASPHERE (2023)

Add to Collection

Editorial Material Hematology

Chasing quality remission in acute myeloid leukemia: intensity of induction and residual disease

Yishai Ofran

HAEMATOLOGICA (2023)

Add to Collection

Article Andrology

A 10-year experience in testicular tissue cryopreservation for boys under 18 years of age: What can be learned from 350 cases?

Virginie Barraud-Lange, Nicolas Boissel, Anne-Sophie Gille, Camille Jean, Leslie Sitbon, Benoit Schubert, Karima Yakouben, Mony Fahd, Matthieu Peycelon, Annabel Paye-Jaouen, Celine Chalas, Alexis Vanhaesebrouck, Francois Doz, Aurore Surun, Lauriane Lemelle, Sabine Sarnacki, Benedicte Neven, Pascale Philippe-Chomette, Christelle Dufour, Charlotte Rigaud, Guy Leverger, Marie-Dominique Tabone, Sabine Irtan, Corinne Pondaree, Harry Lezeau, Gilles Lenaour, Mathilde Sibony, Eva Comperat, Isabelle Brocheriou, Jean Philippe Wolf, Jean-Hugue Dalle, Catherine Poirot

Summary: This study reviewed 10 years of pediatric fertility preservation activity and found that the process is feasible, acceptable, safe, and potentially useful. The impact of chemotherapy on spermatogonia in testicular tissue was analyzed, and it was found that alkylating agents can reduce the chance of preserving spermatogonia.

ANDROLOGY (2023)

Add to Collection

Article Oncology

Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic TP53-Mutant Clonal Hematopoiesis

Rathana Kim, Hugo Bergugnat, Lise Larcher, Matthieu Duchmann, Marie Passet, Stephanie Gachet, Wendy Cuccuini, Marina Lafage-Pochitaloff, Cedric Pastoret, Nathalie Grardel, Vahid Asnafi, Beat W. Schaefer, Eric Delabesse, Raphael Itzykson, Lionel Ades, Yosr Hicheri, Yves Chalandon, Carlos Graux, Patrice Chevallier, Mathilde Hunault, Thibaut Leguay, Francoise Huguet, Veronique Lheritier, Herve Dombret, Jean Soulier, Philippe Rousselot, Nicolas Boissel, Emmanuelle Clappier

Summary: Low hypodiploidy is a common subtype of B-cell acute lymphoblastic leukemia (B-ALL) in older adults, characterized by somatic TP53 biallelic alteration. The study reveals a link between aging and low hypodiploidy ALL, with TP53-mutant clonal hematopoiesis serving as a preleukemic reservoir that can give rise to aneuploidy and B-ALL.

BLOOD CANCER DISCOVERY (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.